Our group previously demonstrated a strong association between elevated plasma soluble CD13 enzyme activity and newly diagnosed extensive chronic GVHD (cGVHD) in children. As cytotoxic anti-CD13 Abs have been documented after blood and marrow transplant (BMT) in association with CMV infection and cGVHD, we hypothesized that soluble CD13 contributes to cGVHD pathogenesis by induction of CD13 reactive Abs and that anti-CD13 Abs could be additional biomarkers for newly diagnosed pediatric extensive cGVHD. Using prospectively collected plasma samples from pediatric allogeneic BMT (allo-BMT) subjects with cGVHD and controls without cGVHD enrolled in a large multi-institution Children's Oncology Group cGVHD therapeutic trial, we evaluated whether soluble CD13 correlates with induction of anti-CD13 Abs. We found that CD13 reactive Abs are present in a proportion of patients after allo-BMT, but did not seem to correlate with the presence of soluble CD13. Anti-CD13 Abs also did not meet our criteria as a diagnostic biomarker for cGVHD. These data do not confirm that induction of CD13 reactive Abs is a mechanism for cGVHD in children nor are part of the pathogenesis of cGVHD associated with elevated soluble CD13. The exact role of CD13 in cGVHD remains to be determined.
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Introduction
Chronic GVHD (cGVHD) is a multisystem alloimmune and autoimmune disorder complicating 40-70% of patients following allogeneic blood and marrow transplant (allo-BMT). [1] [2] [3] [4] [5] [6] The Children's Oncology Group trial, ASCT0031 ('Phase III Trial of Hydroxychloroquine plus Standard Therapy for Chronic Graft-Versus-Host Disease'), a newly discovered plasma biomarker, elevated soluble CD13 (aminopeptidase N) in subjects developing cGVHD early after allo-BMT. 7, 8 CD13 is an integral membrane protein with enzymatic activity, ubiquitously expressed on a number of tissue types affected by cGVHD, including smooth muscle, endothelial, epithelial and fibroblast cells. 9, 10 The mechanism by which soluble CD13 enzyme activity becomes elevated in cGVHD is unclear. One mechanistic possibility is that soluble CD13 becomes immunogenic once in the plasma, producing cytotoxic anti-CD13 Abs that incite further tissue damage. Cytotoxic anti-CD13 Abs have previously been described in a small series of patients following allo-BMT in association with cGVHD and CMV infection. 11, 12 Similar cGVHD mechanisms have also been reported for Abs reactive with H-Y minor Ags 13 and PDGF receptor. 14 We sought to determine whether (1) soluble CD13 was immunogenic after allo-BMT, leading to the production of anti-CD13 Abs, and (2) whether anti-CD13 Abs met our previously defined criteria 7 as a biomarker of pediatric extensive cGVHD.
Materials and methods

Subjects
Peripheral blood samples were collected and evaluated prospectively from subjects enrolled on the Children's Oncology Group trial ASCT0031, a phase III randomized, placebo-controlled, double-blind trial evaluating two treatment regimens for pediatric subjects with newly diagnosed extensive cGVHD as previously described. 7 Subjects enrolled and treated on ASCT0031 formed the experimental group (n ¼ 52). To control for immune reconstitution following allo-BMT, a time-matched comparison with the control group (n ¼ 28) was performed for the subjects with cGVHD, with days after allo-BMT at the time of cGVHD diagnosis used to divide the experimental group into early-onset cGVHD (3-8 months after transplantation) or late-onset cGVHD (X9 months after transplantation) and compared with control BMT patients without cGVHD from 6 (early) and 12 months (late) after BMT. Healthy volunteer blood donor controls (n ¼ 6) not undergoing transplantation were evaluated for comparison.
Samples evaluated
Peripheral blood was collected from subjects with cGVHD at study entry (time of cGVHD diagnosis) and in control subjects collected at 6 and 12 months (after transplantation). The sample was separated into cells and plasma after centrifugation and stored at À80 1C. Frozen plasma was defrosted in a water bath at 37 1C and ultracentrifuged (15 000 r.p.m. for 5 min) to get rid of precipitate when ready for use. Following our previous analysis of biomarkers, 7 a minority of subjects did not have adequate volume of plasma remaining for anti-CD13 Ab analysis and were not included with this analysis. Adequate plasma was available for anti-CD13 Ab analysis (45 cGVHD samples and 26 controls by ELISA; 42 cGVHD samples and 23 controls by Cellomics, Pittsburgh, PA, USA).
Enzymatic assay of soluble CD13 (aminopeptidase N)
Plasma samples were tested for soluble CD13 (aminopeptidase N) activity as we had previously described. 7 Results of soluble CD13 activity previously reported by our group 7 were used for correlative studies against anti-CD13 Abs.
ELISA for anti-CD13
In all, 100 mg of purified porcine aminopeptidase N/CD13 (Sigma-Aldrich, Oakville, ON, USA, 83% amino-acid homology with human CD13) was diluted in 10 ml of 0.1 M carbonate-bicarbonate buffer (pH 9.5). A volume of 100 ml was added to each well of a polystyrene flat-bottom ELISA plate, incubated overnight at 4 1C, washed three times with Tris-buffered saline containing 0.05% Tween 20, pH 7.4. The nonspecific binding of serum proteins was prevented by adding 200 ml of 1.5% BSA in PBS followed by 2-h incubation at room temperature. Plates were washed as above and 100 ml of 1:100 diluted serum samples were added in duplicate and incubated for 2 h at room temperature. Plates were washed and 100 ml of horseradish peroxidase-conjugated goat anti-human polyspecific Ig (diluted based on the manufacturer's recommendation; Sigma-Aldrich) was added to each well. After 1-h incubation at room temperature, plates were washed with TBS/T five times and 100 ml of the specific substrate, TMB (Sigma-Aldrich), was added. The enzyme reaction was stopped by adding 50 ml of 1 M H 2 SO 4 and the OD was read at 450 nm with a microtiter reader. To detect nonspecific binding, several control wells containing all reagents except human serum or CD13, in addition to wells containing mouse sera, were used.
Cellomics for anti-CD13
Samples (30 ml) were diluted at a ratio of 1:5 in PBS (120 ml) and added to 96-well plates containing nontransfected murine hemangioendothelioma endothelial cells (EOMA cell line) and incubated for 2 h at room temperature to reduce nonspecific binding. Plates were centrifuged (800 r.p.m. for 5 min) and 100 ml of supernatant was harvested. The supernatant was added to 96-well plates containing plasmid-transfected EOMA cells expressing human CD13 Ag and incubated for 2 h at room temperature. Wells were then washed three times with PBS and murine anti-human Ig (with specificity for human IgG) conjugated to FITC (BD Biosciences, Mississauga, ON, Canada) was added, incubated for 30 min and washed with PBS. MoAb WM15 was used as a positive control (1:50 dilution using 2 ml WM15 and 98 ml PBS) and IgG 1 mouse isotype MoAb (Ancell, Bayport, MN, USA) was used as a negative control followed by FITC-conjugated anti-mouse IgG 1 . The HOECHST 33342 dye (Sigma-Aldrich) at 1 mg/ml was used to detect EOMA cell DNA. The FITC intensity of each well was read by ArrayScan 
Statistical analysis
As previously defined, anti-CD13 Abs were considered biologically and clinically important if the following two criteria were met: (1) 100% higher or 50% lower compared with control ( ± 5%) and (2) statistical significance with a P-value o0.05. 7 Descriptive statistics were generated on all data using Prism version 5 for PC (GraphPad Software, San Diego, CA, USA) or SPSS (version 15.0, Chicago, IL, USA). Significance of observed changes was determined using Student's t-test and 95% confidence intervals of the difference expressed. All P-values o0.05 were considered statistically significant.
Results
Subject characteristics
Subjects were compared for differences in age, sex, donor source, donor type and for the presence of acute GVHD, and were previously reported. 7 No significant differences were detected, except cGVHD was more likely in unrelated donor transplantation (29 of 51 (57%) vs 8 of 28 (29%); P ¼ 0.02).
Anti-CD13 Abs
Mean anti-CD13 Abs by ELISA assay were not different comparing early cGVHD (those patients with onset before 9 months) with early controls (no cGVHD at 6 to 9 months and samples collected at 6 months after BMT) (0.40 OD±0.28 vs 0.39 OD±0.24 (s.d.); P ¼ 0.2) or late cGVHD (onset X9 months after BMT) with late controls (samples collected at 12 months in patients who did not develop cGVHD by 18 months) (0.53 OD±0.33 vs 0.57 OD±0.21 (s.d.); P ¼ 0.4) ( Figure 1a ). As the ELISA assay used porcine CD13, we hypothesized that human anti-CD13 Abs may not bind to the porcine Ag. Anti-CD13 detection was therefore repeated by Cellomics using plasmid-transfected EOMA cells (provided by Dr Shapiro) expressing human CD13 on the cell surface. Similarly, no difference in mean Ab levels were detected comparing early cGVHD with early controls (1063 average FITC intensity per cell±639 vs 1008 average FITC intensity per cell±528 (s.d.); P ¼ 0.19) or late cGVHD with late controls (1367 average FITC intensity per cell ± 620 vs 1178 average FITC intensity per cell ± 378 (s.d.); P ¼ 0.34) (Figure 1b ). As a continuous variable, anti-CD13 Abs were not different between cGVHD or control groups (no cGVHD) and did not meet our criteria as a biomarker of cGVHD. Some of the samples from both cGVHD and controls in the Cellomics assay had high anti-CD13 levels compared with healthy volunteers (Figure 1b ). Using a positive anti-CD13 cutoff as the mean FITC intensity per cell plus 2 s.d. for the healthy volunteers, we found no significant difference of positive anti-CD13 Abs between early cGVHD (14 of 32, 44%) and early controls (5 of 22, 23%) (difference 21%; 95% confidence interval: À3.5 to þ 45.6%). Similarly, there was no significant difference in late cGVHD (7 of 10, 70%) compared with late controls (5 of 12, 42%) (difference 28%; 95% confidence interval: À11.5 to þ 68.1%). No association could be found between anti-CD13 Abs (positive or negative) and past history of acute GVHD, nor any particular site of cGVHD involvement (skin, oral, ocular, gastrointestinal, hepatic, pulmonary or musculoskeletal) (data not shown).
Early cGVHD
Anti-CD13 Early controls r = -0.06 P = 0.78 Figure 2 Comparison of anti-CD13 Ab levels by Cellomics with sCD13 activity for subjects with (a) early-onset cGVHD (b) allo-BMT but no cGVHD (blood taken at 6 months after BMT; early controls) (c) late-onset cGVHD (d) allo-BMT but no cGVHD (blood taken 12 months after BMT; late controls).
Correlation of anti-CD13 Abs with sCD13 activity
To evaluate whether soluble CD13 correlates with induction of anti-CD13 Ab, a correlation analysis was performed using Cellomics data and soluble CD13 enzyme activity. There was no correlation with soluble CD13 enzyme activity and anti-CD13 Ab (Figure 2 ; r values: 0.03, À0.06, À0.34 and 0.15 for early cGVHD, early controls, late cGVHD and late controls, respectively.).
Discussion
Having recently shown that soluble CD13 is strongly correlated with newly diagnosed extensive cGVHD in children, 7 combined with the previously identified association of anti-CD13 Abs with CMV infection 11 and cGVHD 12 following BMT, we attempted to determine whether soluble CD13 induced CD13 reactive Abs as a mechanism underlying cGVHD. Our analysis demonstrates that soluble CD13 does not contribute to cGVHD pathogenesis through the induction of CD13 reactive Abs, nor anti-CD13 Abs are biomarkers for extensive cGVHD. Our prevalence of anti-CD13 Abs (23-70%) was consistent with previous reports of anti-CD13 Abs (45%) after BMT. 11 In this previous study, anti-CD13 Abs were found only with CMV viremia or disease. Data on the CMV donor/recipient serostatus and CMV infection patterns after BMT in our study were not collected, making it impossible to evaluate the relationship of anti-CD13 to CMV infection. 15 Anti-CD13 neutralizes CMV infection by interacting with virion-associated CD13 16 and these Abs appears with CMV detection. 11 Therefore, the presence of anti-CD13 Abs may be related to CMV reactivation after allo-BMT as opposed to cGVHD.
The mechanism of elevated soluble CD13 in cGVHD remains unclear. Membrane-bound CD13 is extensively expressed on multiple tissue types including those affected by cGVHD. 9,10 Soluble CD13 may be a nonspecific by-product of intense tissue inflammation. An alternative is that aminopeptidase N is co-expressed with MHC II molecules on a number of professional APCs 17 and the NH 2 -terminal sequence pattern of MHC class II-bound peptides may affect in vivo Ag processing. 18 In conclusion, we demonstrate that soluble CD13 in cGVHD does not induce anti-CD13 Abs, although Abs are present in some subjects after allo-BMT. The mechanism of CD13 in cGVHD pathogenesis remains unclear but may involve mediation of inflammatory responses by T cells.
